Parameter
| Biomarker | del (17p)、t (4;14)、t (14;16)、1q+) | Full name | chromosome abnormality( Deletion of the short arm of chromosome 17、Reciprocal translocation between chromosome 4 and chromosome 14、Reciprocal translocation between chromosome 14 and chromosome 16、Gain/Amplification of the long arm of chromosome 1 | Molecular Type | nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | prognosis, risk stratification | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Multiple Myeloma (MM) | Test Sample / Technology Platform | marrow | ||
| Pathobiological Mechanisms | del(17p) leads to TP53 deletion, t(4;14) activates FGFR3/MMSET, t(14;16) overexpresses c-MAF, and 1q+ amplification of CKS1B, all of which enhance tumor invasiveness. | ||||
| Clinical Availability Status | Routine clinical use/guideline recommendations | ||||
| Notes and Dynamics | High-risk abnormal patients exhibit poor response to conventional regimens, and intensive therapy (e.g., double ASCT, CAR-T) is recommended; the incidence of 1q+ is elevated in relapsed patients and may serve as a resistance monitoring indicator. | ||||